2-(3-Bromomethyl-phenyl)-propionic acid methyl ester | 1218987-96-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-(3-Bromomethyl-phenyl)-propionic acid methyl ester
• 英文别名: methyl 2-[3-(bromomethyl)phenyl]propanoate
• CAS: 1218987-96-2
• 化学式: C₁₁H₁₃BrO₂
• 分子量: 257.127
• InChiKey: IEQFGXLJQCZRNZ-UHFFFAOYSA-N

物化性质

• 沸点：
  293.7±20.0 °C(Predicted)
• 密度：
  1.360±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-butoxy-9H-purin-6-amine 、 2-(3-Bromomethyl-phenyl)-propionic acid methyl ester 在 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 Methyl 2-[3-[(6-amino-2-butoxypurin-9-yl)methyl]phenyl]propanoate
  参考文献：
  名称：

  Synthesis and Biological Evaluation of 8-Oxoadenine Derivatives as Toll-like Receptor 7 Agonists Introducing the Antedrug Concept

  摘要：

  Systemic administration of a Toll-like receptor 7 (TLR7) agonist is effective to in suppressing Th2 derived inflammation, however systemic induction of various cytokines such as IL-6, IL-12, and type I interferon (IFN) is observed. This cytokine induction would be expected to cause flu-like symptoms. We have previously reported adenine compounds (3, 4) as interferon inducing agents acting as TLR7 agonists. To identify potent anti-inflammatory compounds without systemic side effects, a labile carboxylic ester as an antedrug functionality onto the N(9)-benzyl group of the adenine was introduced. We found that 9e was a potent TLR7 agonist (EC(50) 50 nM) and rapidly metabolized by human plasma (T(1/2)2.6 min) to the pharmacologically much less active carboxylic acid 16. Intratracheal administration of 9e effectively inhibited allergen-induced airway inflammation without inducing cytokines systemically. Therefore, the TLR7 agonist with antedrug characteristics 9e (SM-324405) is a novel candidate for immunotherapy of allergic diseases.

  DOI：

  10.1021/jm100070n

文献信息

• SPIRO IMIDOZOLE DERIVATIVES AS PPAR MODULATORS
  申请人：Epple Robert

  公开号：US20090137610A1

  公开（公告）日：2009-05-28

  The invention provides compounds (Ia), (Ib) and (Ic), pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of the Peroxisome Proliferator-Activated Receptor (PPAR) families.

  本发明提供了化合物(Ia)、(Ib)和(Ic)，包括此类化合物的制药组合物以及使用这些化合物治疗或预防与过氧化物酶体增殖物激活受体（PPAR）家族活性相关的疾病或障碍的方法。
• SPIRO IMIDAZOLE DERIVATIVES AS PPAR MODULATORS
  申请人：IRM LLC

  公开号：EP1979355A1

  公开（公告）日：2008-10-15
• [EN] SPIRO IMIDAZOLE DERIVATIVES AS PPAR MODULATORS<br/>[FR] DÉRIVÉS D'IMADAZOLE SPIRO UTILISÉS COMME MODULATEURS DU RÉCEPTEUR PPAR
  申请人：IRM LLC

  公开号：WO2007087448A1

  公开（公告）日：2007-08-02

  [EN] The invention provides compounds (Ia), (Ib) and (Ic), pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of the Peroxisome Proliferator-Activated Receptor (PPAR) families.
  [FR] La présente invention concerne des composés (Ia), (ib) et (Ic), des compositions pharmaceutiques comprenant ces composés et des procédés d'utilisation de ces composés destinés à traiter ou prévenir des maladies ou des troubles associés à l'activité des familles du récepteur activé par les proliférateurs de peroxisome (PPAR).
• Synthesis and Biological Evaluation of 8-Oxoadenine Derivatives as Toll-like Receptor 7 Agonists Introducing the Antedrug Concept
  作者：Ayumu Kurimoto、Kazuki Hashimoto、Tomoaki Nakamura、Kei Norimura、Haruhisa Ogita、Haruo Takaku、Roger Bonnert、Tom McInally、Hiroki Wada、Yoshiaki Isobe

  DOI：10.1021/jm100070n

  日期：2010.4.8

  Systemic administration of a Toll-like receptor 7 (TLR7) agonist is effective to in suppressing Th2 derived inflammation, however systemic induction of various cytokines such as IL-6, IL-12, and type I interferon (IFN) is observed. This cytokine induction would be expected to cause flu-like symptoms. We have previously reported adenine compounds (3, 4) as interferon inducing agents acting as TLR7 agonists. To identify potent anti-inflammatory compounds without systemic side effects, a labile carboxylic ester as an antedrug functionality onto the N(9)-benzyl group of the adenine was introduced. We found that 9e was a potent TLR7 agonist (EC(50) 50 nM) and rapidly metabolized by human plasma (T(1/2)2.6 min) to the pharmacologically much less active carboxylic acid 16. Intratracheal administration of 9e effectively inhibited allergen-induced airway inflammation without inducing cytokines systemically. Therefore, the TLR7 agonist with antedrug characteristics 9e (SM-324405) is a novel candidate for immunotherapy of allergic diseases.